Peter Staib

Winterhäuser Str. 85, 
Wuerzburg, BY, DE 
Winterhäuser Str. 85, 
Wuerzburg, BY, DE 

Overview

Peter Staib practices practicing medicine in Wuerzburg, Germany.

His clinical expertise encompasses Leukemia, Multiple Myeloma, Triple-Negative Breast Cancer, Breast Cancer, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Winterhäuser Str. 85, Wuerzburg, BY 97084, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3

57 Total Publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.
Journal: BMC cancer
Published: June 16, 2026

Frequently Asked Questions about Peter Staib

Is Peter Staib a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Peter Staib is classified as an Experienced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Peter Staib participate in research or clinical trials?

Yes. Peter Staib has published 57 articles and abstracts on conditions like Leukemia. You can view a list of Peter Staib's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Staib's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile